Climb Bio, Inc. also files under CLYM; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | Ra Capital Management, L.P. | Director, 10% Owner | Grant(A) | 70K | — | $0 |
| Jun 29, 2026 | Celebi Breanna Maurine | Director | Grant(A) | 70K | — | $0 |
| Jun 29, 2026 | Brennan Aoife | President and CEO, Director | Sell(S) | 31K | $13.17 | $407K |
| Jun 27, 2026 | Brennan Aoife | President and CEO, Director | Option exercise(M) | 69K | — | $0 |
| Jun 27, 2026 | Brennan Aoife | President and CEO, Director | Option exercise(M) | 69K | — | — |
| Jun 5, 2026 | Levin Andrew David | Director | Grant(A) | 40K | — | $0 |
| Jun 5, 2026 | Ra Capital Management, L.P. | Director, 10% Owner | Grant(A) | 40K | — | $0 |
| Jun 5, 2026 | Cumbo Alexander | Director | Grant(A) | 40K | — | $0 |
| Jun 5, 2026 | Dunn Judith | Director | Grant(A) | 40K | — | $0 |
| Jun 5, 2026 | Williams Douglas E | Director | Grant(A) | 40K | — | $0 |
| Jun 5, 2026 | Thomas Stephen Basil | Director | Grant(A) | 40K | — | $0 |
| Jun 5, 2026 | Drapkin Kimberlee C | Director | Grant(A) | 40K | — | $0 |
| Apr 29, 2026 | Ra Capital Management, L.P. | Director, 10% Owner | Grant(A) | 2.1M | $9.50 | $20.0M |
| Feb 26, 2026 | Thomas Stephen Basil | Director | Sell(S) | 16K | $7.01 | $114K |
| Feb 25, 2026 | Thomas Stephen Basil | Director | Sell(S) | 34K | $7.00 | $236K |
| Feb 13, 2026 | Thomas Stephen Basil | Director | Sell(S) | 10K | $5.81 | $58K |
| Feb 12, 2026 | Thomas Stephen Basil | Director | Sell(S) | 90K | $5.23 | $471K |
| Jan 6, 2026 | Driscoll Cindy | Senior Vice President, Finance | Grant(A) | 100K | — | $0 |
| Jan 6, 2026 | Altschuller Susan | Chief Financial Officer | Grant(A) | 143K | — | $0 |
| Jan 6, 2026 | Wilson Perrin Megan | Chief Business Officer | Grant(A) | 300K | — | $0 |
| Jan 6, 2026 | Brennan Aoife | President and CEO, Director | Grant(A) | 700K | — | $0 |
| Jan 5, 2026 | RA Capital Healthcare Fund LP | Director, 10% Owner | Buy(P) | 7K | $3.50 | $25K |
| Dec 12, 2025 | Kolchinsky Peter | Director, 10% Owner | Buy(P) | 101K | $2.86 | $290K |
| Dec 11, 2025 | Kolchinsky Peter | Director, 10% Owner | Buy(P) | 213K | $2.18 | $465K |
| Dec 11, 2025 | Kolchinsky Peter | Director, 10% Owner | Disposed to issuer(D) | 20.4M | — | $0 |
| Dec 11, 2025 | Kolchinsky Peter | Director, 10% Owner | Grant(A) | 20.4M | — | — |
| Oct 1, 2025 | Altschuller Susan | Chief Financial Officer | Grant(A) | 600K | — | $0 |
| Aug 7, 2025 | Thomas Stephen Basil | Director | Grant(A) | 100K | — | $0 |
| Jun 30, 2025 | Brennan Aoife | President and CEO, Director | Sell(S) | 21K | $1.22 | $25K |
| Jun 27, 2025 | Brennan Aoife | President and CEO, Director | Option exercise(M) | 69K | — | $0 |
| Jun 27, 2025 | Brennan Aoife | President and CEO, Director | Option exercise(M) | 69K | — | — |
| Jun 27, 2025 | Thomas Stephen Basil | Director | Option exercise(M) | 25K | — | — |
| Jun 27, 2025 | Thomas Stephen Basil | Director | Option exercise(M) | 25K | — | $0 |
| Jun 20, 2025 | Pimblett Emily | SVP, Finance & CAO | Sell(S) | 1K | $1.24 | $2K |
| Jun 18, 2025 | Pimblett Emily | SVP, Finance & CAO | Option exercise(M) | 5K | — | — |
| Jun 18, 2025 | Pimblett Emily | SVP, Finance & CAO | Option exercise(M) | 5K | — | $0 |
| Jun 17, 2025 | Driscoll Cindy | Senior Vice President, Finance | Grant(A) | 200K | — | $0 |
| Jun 4, 2025 | Dunn Judith | Director | Grant(A) | 40K | — | $0 |
| Jun 4, 2025 | Cumbo Alexander | Director | Grant(A) | 40K | — | $0 |
| Jun 4, 2025 | RA Capital Healthcare Fund LP | Director, 10% Owner | Grant(A) | 40K | — | $0 |
| Jun 4, 2025 | Williams Douglas E | Director | Grant(A) | 40K | — | $0 |
| Jun 4, 2025 | Levin Andrew David | Director | Grant(A) | 40K | — | $0 |
| Jun 4, 2025 | Thomas Stephen Basil | Director | Grant(A) | 40K | — | $0 |
| Jun 4, 2025 | Drapkin Kimberlee C | Director | Grant(A) | 40K | — | $0 |
| Mar 31, 2025 | Williams Douglas E | Director | Grant(A) | 79K | — | $0 |
| Mar 28, 2025 | Drapkin Kimberlee C | Director | Grant(A) | 80K | — | $0 |
| Mar 28, 2025 | Cumbo Alexander | Director | Grant(A) | 80K | — | $0 |
| Mar 27, 2025 | Thomas Stephen Basil | Director | Option exercise(M) | 25K | — | — |
| Mar 27, 2025 | Thomas Stephen Basil | Director | Option exercise(M) | 25K | — | $0 |
| Mar 20, 2025 | Pimblett Emily | SVP, Finance & CAO | Sell(S) | 1K | $1.31 | $2K |
| Mar 18, 2025 | Pimblett Emily | SVP, Finance & CAO | Option exercise(M) | 5K | — | $0 |
| Mar 18, 2025 | Pimblett Emily | SVP, Finance & CAO | Option exercise(M) | 5K | — | — |
| Jan 13, 2025 | Pimblett Emily | SVP, Finance and CAO | Grant(A) | 100K | — | $0 |
| Jan 13, 2025 | Brennan Aoife | President and CEO, Director | Grant(A) | 1.1M | — | $0 |
| Jan 13, 2025 | Kaplan Brett | Chief Operating Officer | Grant(A) | 500K | — | $0 |
| Jan 1, 2025 | Thomas Stephen Basil | Director | Option exercise(M) | 50K | — | — |
| Jan 1, 2025 | Thomas Stephen Basil | Director | Option exercise(M) | 50K | — | $0 |
| Dec 19, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Sell(S) | 1K | $2.02 | $2K |
| Dec 18, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Option exercise(M) | 5K | — | $0 |
| Dec 18, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Option exercise(M) | 5K | — | — |
| Nov 11, 2024 | Williams Douglas E | Director | Grant(A) | 20K | — | $0 |
| Nov 11, 2024 | Williams Douglas E | Director | Grant(A) | 6K | — | $0 |
| Sep 20, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Sell(S) | 1K | $8.18 | $10K |
| Sep 20, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Sell(S) | 9 | $8.06 | $73 |
| Sep 18, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Option exercise(M) | 5K | — | $0 |
| Sep 18, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Option exercise(M) | 5K | — | — |
| Aug 26, 2024 | Kaplan Brett | Chief Operating Officer | Grant(A) | 465K | — | $0 |
| Aug 26, 2024 | Kaplan Brett | Chief Operating Officer | Grant(A) | 78K | — | $0 |
| Jul 22, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 30K | $7.98 | $239K |
| Jul 22, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 39K | $8.07 | $315K |
| Jul 19, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 50K | $7.24 | $362K |
| Jul 19, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 10K | $7.09 | $72K |
| Jul 18, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 39K | $6.93 | $267K |
| Jul 17, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 3K | $6.91 | $22K |
| Jul 16, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 50K | $7.13 | $357K |
| Jul 15, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 42K | $7.01 | $297K |
| Jul 12, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 50K | $7.07 | $354K |
| Jul 11, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 50K | $7.11 | $356K |
| Jul 10, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 50K | $6.83 | $342K |
| Jul 9, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 6K | $6.66 | $40K |
| Jul 5, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 12K | $7.06 | $87K |
| Jul 3, 2024 | Morisset Valerie | EVP, R&D AND CSO | Sell(S) | 50K | $6.76 | $338K |
| Jul 1, 2024 | Morisset Valerie | EVP, R&D AND CSO | Option exercise(M) | 8K | — | $0 |
| Jul 1, 2024 | Morisset Valerie | EVP, R&D AND CSO | Option exercise(M) | 8K | — | $0 |
| Jun 27, 2024 | Kolchinsky Peter | Director, 10% Owner | Grant(A) | 2.5M | — | — |
| Jun 27, 2024 | Kolchinsky Peter | Director, 10% Owner | Grant(A) | 1.8M | — | — |
| Jun 27, 2024 | Kolchinsky Peter | Director, 10% Owner | Grant(A) | 973K | — | — |
| Jun 27, 2024 | Kolchinsky Peter | Director, 10% Owner | Buy(P) | 11.9M | $3.84 | $45.9M |
| Jun 27, 2024 | Kolchinsky Peter | Director, 10% Owner | Buy(P) | 1.1M | $3.84 | $4.1M |
| Jun 27, 2024 | Thomas Stephen Basil | Director | Grant(A) | 104K | — | — |
| Jun 27, 2024 | Thomas Stephen Basil | Director | Grant(A) | 100K | — | $0 |
| Jun 27, 2024 | Brennan Aoife | President and CEO, Director | Grant(A) | 550K | — | $0 |
| Jun 27, 2024 | Brennan Aoife | President and CEO, Director | Grant(A) | 275K | — | $0 |
| Jun 26, 2024 | Ratcliffe Liam | Director | Grant(A) | 10K | — | $0 |
| Jun 26, 2024 | Dunn Judith | Director | Grant(A) | 10K | — | $0 |
| Jun 26, 2024 | Rosenberg Adam Joseph | Director | Grant(A) | 10K | — | $0 |
| Jun 26, 2024 | Levin Andrew David | Executive Chairman, Director | Grant(A) | 10K | — | $0 |
| Jun 26, 2024 | Kolchinsky Peter | Director, 10% Owner | Grant(A) | 10K | — | $0 |
| Jun 26, 2024 | Tate Simon | Director | Grant(A) | 10K | — | $0 |
| Jun 20, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Sell(S) | 1K | $7.21 | $9K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Climb Bio, Inc., SEC CIK 0001768446. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ELYM and shows every filing by that issuer (also filed as CLYM).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-05. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ELYM